Iowa Medicaid Drug Utilization Review Commission

Iowa Medicaid Drug Utilization Review Commission

Attention Physicians: Are you looking for a new professional opportunity?

CMS requires state Medicaid programs to have a drug utilization review (DUR) program consisting of prospective DUR, retrospective DUR, and an educational program. The goal of the DUR program is to ensure appropriate medication therapy, while permitting appropriate professional judgment to individualize medication therapy. In Iowa, the DUR Board is referred to as the Iowa Medicaid DUR Commission. The Iowa DUR Commission is composed of four Iowa licensed physicians and four Iowa licensed pharmacists who serve up to two, four-year terms, as well as a representative from the Department of Human Services. The Commission meets on the first Wednesday six months of the year from 9:30 a.m. to 1:30 p.m.

The DUR Commission is currently seeking a Physician who serves Medicaid Members to join the committee. Any Physician interested in serving in this capacity should send a resume or curriculum vitae, as well as a letter indicating their interest to Pamela Smith at the address shown below. Candidates that would like more information about the Commission or who would like to speak to a present Commissioner are encouraged to call.

The deadline for applications is April 1, 2015.

Pamela Smith, R.Ph.
DUR Project Coordinator
Iowa Medicaid Drug Utilization Review Commission
100 Army Post Road
Des Moines, IA 50315
(515) 974-3131
info@iadur.org

New Public Comment Policy

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to 5 minutes or less. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Multiple representatives from a single organization will also be required to share the 5 minutes.

Data that is to be referenced during the Public Comment period(s) should be limited to published, peer reviewed literature only. “Data on file” and “articles submitted for review” are not considered published, peer reviewed literature and should not be referenced during public testimony.

All referenced data that is to be presented should be submitted to the DUR professional staff electronically to info@iadur.org AT LEAST ONE WEEK PRIOR TO THE MEETING DATE for consideration and distribution to the Commission members. The deadline is 4:30 P.M. CT Wednesday, before the scheduled meeting date. Anything submitted to the DUR professional staff after this deadline will be distributed to the Commission members for the next scheduled DUR meeting.

Recent Site Updates

New meeting information has been added.
A new DUR Digest has been added.

DUR Commission Members

  • Mark Graber, M.D., FACEP, Chairperson
  • Laurie Pestel, Pharm.D., Vice Chairperson
  • Larry Ambroson, R.Ph.
  • Gregory Barclay, M.D.
  • Brian Couse, M.D.
  • Brett Faine, Pharm.D.
  • Kellen Ludvigson, Pharm.D.
  • Susan Parker, Pharm.D.
  • Jason Wilbur, M.D.

More information

Professional Staff

  • Pam Smith, R.Ph. - DUR Project Coordinator